Peter Biberfeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Biberfeld has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Fatemeh Pak
Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran
3 shared publications - Amos R Mwakigonja
Immunopathology Lab., Cancer Center Karolinska (CCK), Department of Oncology-Pathology, Karolinska University Hospital Solna/Karolinska Institute, Stockholm, Sweden
2 shared publications - Ephata E Kaaya
Immunopathology Lab., Cancer Center Karolinska (CCK), Department of Oncology-Pathology, Karolinska University Hospital Solna/Karolinska Institute, Stockholm, Sweden
2 shared publications - Amos R. Mwakigonja
Department of Pathology, Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania
1 shared publication - Anna Porwit
Department of Pathology, Radiumhemmet, Karolinska University Hospital Solna, Stockholm, Sweden
1 shared publication - Ephata Kaaya
Immunopathology Lab., Department of Pathology and Oncology, Karolinska Institutet, 171-76 Solna, Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 1 July 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 344
Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association
In Tanzania, the International Working Formulation [WF] rather than the WHO Classification is still being used in diagnosing malignant lymphomas (ML) and the biological characterization including the HIV/EBV association is sketchy, thus restraining comparison, prognostication and application of established therapeutic protocols.
- 1 July 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 344
Open AccessTanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association
In Tanzania, the International Working Formulation [WF] rather than the WHO Classification is still being used in diagnosing malignant lymphomas (ML) and the biological characterization including the HIV/EBV association is sketchy, thus restraining comparison, prognostication and application of established therapeutic protocols.
- Open Access
- 30 June 2008
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 3 (1) , 10
Human herpesvirus-8 (HHV-8) sero-detection and HIV association in Kaposi's sarcoma (KS), non-KS tumors and non-neoplastic conditions
The association of the human herpesvirus-8/Kaposi's sarcoma (KS)-associated herpesvirus (HHV-8/KSHV) serology with various malignancies in Tanzania is not currently well established while previous studies were based on either PCR or immunofluorescence assays [IFA] but not with a sensitive enzyme-linked immunosorbent assay (ELISA). Selected archival diagnostic biopsies (n = 184) and sera from indigenous patients with KS (n = 120), non-KS tumors (n = 24) and non-neoplastic lesions (n = 40) at Muhimbili National Hospital (MNH), Tanzania, were evaluated by diagnostic histopathology, immunohistology [anti-HHV-8 latency-associated nuclear antigen (LANA)] and serology for HIV (ELISA) and HHV-8 (IFA and ELISA).
- 30 June 2008
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 3 (1) , 10
Open AccessHuman herpesvirus-8 (HHV-8) sero-detection and HIV association in Kaposi's sarcoma (KS), non-KS tumors and non-neoplastic conditions
The association of the human herpesvirus-8/Kaposi's sarcoma (KS)-associated herpesvirus (HHV-8/KSHV) serology with various malignancies in Tanzania is not currently well established while previous studies were based on either PCR or immunofluorescence assays [IFA] but not with a sensitive enzyme-linked immunosorbent assay (ELISA). Selected archival diagnostic biopsies (n = 184) and sera from indigenous patients with KS (n = 120), non-KS tumors (n = 24) and non-neoplastic lesions (n = 40) at Muhimbili National Hospital (MNH), Tanzania, were evaluated by diagnostic histopathology, immunohistology [anti-HHV-8 latency-associated nuclear antigen (LANA)] and serology for HIV (ELISA) and HHV-8 (IFA and ELISA).
- Open Access
- 2 February 2007
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 2 (1) , 4
KSHV/HHV-8 and HIV infection in Kaposi's sarcoma development
Kaposi's sarcoma (KS) is a highly and abnormally vascularized tumor-like lesion affecting the skin, lymphnodes and viscera, which develops from early inflammatory stages of patch/plaque to late, nodular tumors composed predominant of spindle cells (SC). These SC are infected with the Kaposi's sarcoma-associated herpesvirus or human herpesvirus-8 (KSHV/HHV-8). KS is promoted during HIV infection by various angiogenic and pro-inflammatory factors including HIV-Tat. The latency associated nuclear antigen type 1 (LANA-1) protein is well expressed in SC, highly immunogenic and considered important in the generation and maintenance of HHV-8 associated malignancies. Various studies favour an endothelial origin of the KS SC, expressing "mixed" lymphatic and vascular endothelial cell markers, possibly representing hybrid phenotypes of endothelial cells (EC). A significant number of SC during KS development are apparently not HHV8 infected, which heterogeneity in viral permissiveness may indicate that non-infected SC may continuously be recruited in to the lesion from progenitor cells and locally triggered to develop permissiveness to HHV8 infection. In the present study various aspects of KS pathogenesis are discussed, focusing on the histopathological as well as cytogenetic and molecular genetic changes in KS.
- 2 February 2007
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 2 (1) , 4
Open AccessKSHV/HHV-8 and HIV infection in Kaposi's sarcoma development
Kaposi's sarcoma (KS) is a highly and abnormally vascularized tumor-like lesion affecting the skin, lymphnodes and viscera, which develops from early inflammatory stages of patch/plaque to late, nodular tumors composed predominant of spindle cells (SC). These SC are infected with the Kaposi's sarcoma-associated herpesvirus or human herpesvirus-8 (KSHV/HHV-8). KS is promoted during HIV infection by various angiogenic and pro-inflammatory factors including HIV-Tat. The latency associated nuclear antigen type 1 (LANA-1) protein is well expressed in SC, highly immunogenic and considered important in the generation and maintenance of HHV-8 associated malignancies. Various studies favour an endothelial origin of the KS SC, expressing "mixed" lymphatic and vascular endothelial cell markers, possibly representing hybrid phenotypes of endothelial cells (EC). A significant number of SC during KS development are apparently not HHV8 infected, which heterogeneity in viral permissiveness may indicate that non-infected SC may continuously be recruited in to the lesion from progenitor cells and locally triggered to develop permissiveness to HHV8 infection. In the present study various aspects of KS pathogenesis are discussed, focusing on the histopathological as well as cytogenetic and molecular genetic changes in KS.